
|Articles|October 12, 2019
Prescriber's Guide to Lasmiditan
In October 2019, the FDA approved Eli Lilly's lasmiditan, marketed as Reyvow, for the acute treatment of migraine with or without aura in adults. The drug is the first approved from a new class of serotonin (5-HT)1F receptor agonists. This downloadable PDF serves as a convenient, consolidated prescribing guide to help you incorporate this new migraine therapy into your clinical practice.
Advertisement
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Therapeutic Potential and Early Promise Behind Stem Cell Therapy UX-DA001 in Parkinson Disease
2
Fenebrutinib Hits Key Phase 3 Marks in Relapsing and Primary Progressive MS
3
Uniting Organizations to Collectively Advocate for Neuromuscular Diseases: Paul Melmeyer, MPP
4
BridgeBio Pursues FDA Submission for BBP-418 in LGMD2i/R9 After Positive Topline Phase 3 Results
5



































